Your browser doesn't support javascript.
loading
Colorectal Cancer Immunotherapy: State of the Art and Future Directions.
Cornista, Alyssa Mauri; Giolito, Maria Virginia; Baker, Kristi; Hazime, Hajar; Dufait, Inès; Datta, Jashodeep; Khumukcham, Saratchandra Singh; De Ridder, Mark; Roper, Jatin; Abreu, Maria T; Breckpot, Karine; Van der Jeught, Kevin.
Afiliação
  • Cornista AM; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida.
  • Giolito MV; Department of Biomedical Sciences, Vrije Universiteit Brussel, Laboratory for Molecular and Cellular Therapy, Brussels, Belgium.
  • Baker K; Department of Oncology, University of Alberta, Edmonton, Canada.
  • Hazime H; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.
  • Dufait I; Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, Florida.
  • Datta J; Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Khumukcham SS; Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • De Ridder M; Division of Surgical Oncology, Dewitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
  • Roper J; Division of Gastroenterology, Department of Medicine, Duke University, Durham, North Carolina.
  • Abreu MT; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.
  • Breckpot K; Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Van der Jeught K; Division of Gastroenterology, Department of Medicine, Duke University, Durham, North Carolina.
Gastro Hep Adv ; 2(8): 1103-1119, 2023.
Article em En | MEDLINE | ID: mdl-38098742
ABSTRACT
Cancer immunotherapy has become an indispensable mode of treatment for a multitude of solid tumor cancers. Colorectal cancer (CRC) has been one of the many cancer types to benefit from immunotherapy, especially in advanced disease where standard treatment fails to prevent recurrence or results in poor survival. The efficacy of immunotherapy in CRC has not been without challenge, as early clinical trials observed dismal responses in unselected CRC patients treated with checkpoint inhibitors. Many studies and clinical trials have since refined immunotherapies available for CRC, solidifying immunotherapy as a powerful asset for CRC treatment. This review article examines CRC immunotherapies, from their foundation, through emerging avenues for improvement, to future directions.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article